Imatinib mesylate is a tyrosine kinase inhibitor used as first-line treatment in Philadelphia
chromosome–positive chronic myeloid leukemia (Ph+ CML) and metastatic or unresectable …

Oncology drug development is a long and costly process associated with a success rate of 5–
10%. The parallel development of companion diagnostic tests that will identify patients most …

Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) tyrosine kinase
inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML) …

Imatinib is a small-molecule tyrosine kinase inhibitor with large inter-individual but low intra-
individual pharmacokinetic variability with consistent concentration–efficacy and …

Chronic myeloid leukemia (CML) is a malignant disease that originates in the bone marrow
and is designated by the presence of the Philadelphia (Ph+) chromosome, a translocation …

Imatinib mesylate (Gleevec) is an effective treatment for chronic myeloid leukemia (CML).
Though cytogenetic and molecular analyses are essential disease monitoring parameters in …

The clinical outcome for patients with chronic myeloid leukemia in chronic phase (CML-CP)
is currently very favorable due to the availability of tyrosine kinase inhibitors (TKIs) that are …

Survival of chronic myelogenous leukemia (CML) cells is dependent on BCR–ABL kinase,
the activity of which is contingent on the level of BCR–ABL protein and the availability of …

Résumé La leucémie myéloïde chronique (LMC) est une hémopathie chronique
caractérisée par une translocation réciproque entre les chromosomes 9 et 22 conduisant à …

Background: The cyto-genetic hallmark of chronic myeloid leukaemia (CML), the
Philadelphia chromosome (Ph), is the first consistent chromosomal abnormality that has …